Literature DB >> 19769684

Fluoroquinolone-induced immune thrombocytopenia: a report and review.

C Y Cheah1, B De Keulenaer, M F Leahy.   

Abstract

Fluoroquinolones are an emerging but underrecognized cause of drug-induced thrombocytopenia. Due to their broad spectrum they are often used in empirical treatment of febrile neutropenic, thrombocytopenic patients following myelosuppressive chemotherapy. They are associated with a range of immunohaematopathology. A 76-year-old male developed severe thrombocytopenia following treatment with ciprofloxacin on two occasions for community-acquired pneumonia. The temporal association, response to dechallenge, dramatic response to rechallenge and exclusion of other causes combined with detection of platelet-reactive antibodies of the immunoglobulin G class against glycoprotein IIb/IIIa following ciprofloxacin rechallenge makes causality probable. We present a brief review of immunohaematopathology associated with fluoroquinolones and draw attention to the structural similarity between quinolones and quinine to explore potential mechanisms for the phenomenon. Fluoroquinolones can induce drug-dependent, platelet-reactive antibodies causing complement-mediated destruction of platelets. The underlying mechanism to explain this is unclear; however, we hypothesize that the chemical similarities shared with quinine may be contributory. When using these agents clinicians should be aware of the possibility of drug-induced thrombocytopenia or thrombotic thrombocytopenic purpura.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19769684     DOI: 10.1111/j.1445-5994.2009.01996.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  7 in total

1.  Drug-induced immune thrombocytopenia due to moxifloxacin.

Authors:  Timothy J Coker
Journal:  BMJ Case Rep       Date:  2013-01-17

2.  Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Authors:  Gregory S Basarab; Gunther H Kern; John McNulty; John P Mueller; Kenneth Lawrence; Karthick Vishwanathan; Richard A Alm; Kevin Barvian; Peter Doig; Vincent Galullo; Humphrey Gardner; Madhusudhan Gowravaram; Michael Huband; Amy Kimzey; Marshall Morningstar; Amy Kutschke; Sushmita D Lahiri; Manos Perros; Renu Singh; Virna J A Schuck; Ruben Tommasi; Grant Walkup; Joseph V Newman
Journal:  Sci Rep       Date:  2015-07-14       Impact factor: 4.379

3.  The potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trial.

Authors:  Maria Egede Johansen; Jens-Ulrik Jensen; Morten Heiberg Bestle; Lars Hein; Anne Øberg Lauritsen; Hamid Tousi; Kim Michael Larsen; Jesper Løken; Thomas Mohr; Katrin Thormar; Pär I Johansson; Alessandro Cozzi-Lepri; Jens D Lundgren
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

4.  Antimicrobial-Induced Cytopenia and Bone Marrow Hypocellularity in Patients with Cirrhosis.

Authors:  Anupama Patil; Vikas Khillan; Monika Thakur; Pratibha Kale; Chhagan Bihari
Journal:  Bone Marrow Res       Date:  2018-05-14

5.  Moxifloxacin (avelox) induced thrombotic thrombocytopenic purpura.

Authors:  Sikander P Surana; Zahily Sardinas; Alan S Multz
Journal:  Case Rep Med       Date:  2012-04-11

6.  Ciprofloxacin-Induced Thrombotic Thrombocytopenic Purpura: A Case of Successful Treatment and Review of the Literature.

Authors:  Hafiz Rizwan Talib Hashmi; Gilda Diaz-Fuentes; Preeti Jadhav; Misbahuddin Khaja
Journal:  Case Rep Crit Care       Date:  2015-10-26

7.  Probable Levofloxacin-Induced Thrombocytopenia in a Patient Previously on Ciprofloxacin: A Case Report and Literature Review.

Authors:  A Justine Landi; Robert Burkes
Journal:  Case Rep Med       Date:  2016-01-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.